Source-grounded facts extracted from INVO Fertility, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INVO Fertility, Inc. reported first quarter ended March 31, 2026 results: revenue $2,015,225, net income $(5.5) million.
“announced financial results for the first quarter ended March 31, 2026. Q1 2026 Financial Highlights (all metrics compared to Q1 2025 unless otherwise noted) ● Revenue was $2,015,225, an increase of 23% compared to $1,637,185. ● Consolidated clinic revenue increased 22% to $1,982,233, compared to $1,621,553. ● Net loss from continuing operations was $(5.5)”
INVO Fertility, Inc. reported fiscal year 2025 results: revenue $6,841,250, net income $(5.3) million.
“and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including”
INVO Fertility, Inc. reported that prior financial statements should not be relied upon.
“On June 1, 2026, the audit committee of the Company, after considering the recommendations of management, concluded that the Company’s previously issued unaudited consolidated financial statements contained within its (i) Quarterly Report on Form 10-Q as of March 31, 2025 and for the three months then ended, filed with the Securities and Exchange Commission (“SEC”) on May 20, 2025, (ii) Quarterly Report on Form 10-Q as of June 30, 2025 and for the three and six months then ended, filed with the SEC on August 14, 2025, and (iii) Quarterly Report on Form 10-Q as of September 30, 2025 and for the three and nine months then ended, filed with the SEC on November 17, 2025 should no longer be relied due the 2025 Financial Statement Errors.”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 23, 2026, INVO Fertility, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to fi”
INVO Fertility, Inc.: Filed a Certificate of Change with the Nevada Secretary of State to effectuate a 1-for-5 reverse stock split of common stock (effective 2026-03-27).
“On March 25, 2026, INVO Fertility, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on Friday, March 27, 2026”
INVO Fertility, Inc. issued 400 shares of the Company's Series D Non-Voting Convertible Preferred Stock of preferred stock to the Seller.
“On February 18, 2026, the Company issued 400 shares of the Company's Series D Non-Voting Convertible Preferred Stock (the "Series D Preferred") to the Seller.”
INVO Fertility, Inc.: Filed Series D Certificate of Designation to establish rights, preferences, and privileges of Series D Preferred Stock (effective 2026-02-18).
“On February 18, 2026, we filed with the Nevada Secretary of State the Series D Certificate of Designation, which sets forth the rights, preferences, and privileges of the Series D Preferred.”
INVO Fertility, Inc. completed an acquisition involving Family Beginnings P.C. (the Clinic) for $760,000 (closed 2026-02-18).
“On February 18, 2026, the Company, through Buyer, consummated its acquisition (the “Acquisition”) of Family Beginnings P.C. (the “Clinic”) for a combined purchase price of $760,000, of which $360,000 was paid in cash on the closing date (a net amount of $210,000 after a $150,000 holdback) and $400,000 was paid on the closing date in 400 shares of the Company’s Series D Preferred”
INVO Fertility, Inc. issued 9,467,456 shares of Common Stock of warrant to institutional investor for The holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share, resulting in gross proceeds of approximately $7.5 m.
“(the “SEC”) on December 29, 2025. Pursuant to the Inducement Letter Agreement, the Holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share in consideration for the Company’s agreement to issue new unregistered warrants to purchase up to an aggregate of 9,467,456 shares of Common Stock at an exercise price”
INVO Fertility, Inc. entered into Inducement Letter Agreement with an institutional investor and existing holder valued at approximately $7.5 million (effective 2026-01-28).
“On January 28, 2026, INVO Fertility, Inc. (the “Company”) entered into an inducement letter agreement (the “Inducement Letter Agreement”) with an institutional investor and existing holder (the “Holder”) of certain existing warrants (the “Existing Warrants”) to purchase up to 4,733,728 shares of the Company’s common stock (the “Common Stock”).”
INVO Fertility, Inc.: Increased authorized shares of common stock from 6,250,000 to 250,000,000 (effective 2026-01-22).
“On January 22, 2026, the Company filed a Certificate of Amendment (the “Amendment”) to its Articles of Incorporation to increase its authorized shares of common stock from 6,250,000 shares to 250,000,000 shares.”
INVO Fertility, Inc. entered into APA with Family Beginnings, P.C. and James Donahue MD valued at combined purchase price of $750,000 (effective 2025-12-15).
“entered into an asset purchase agreement by and among the Buyer, Family Beginnings, P.C., an Indiana professional service corporation (the "Seller"), and James Donahue MD ("Dr. Donahue") (the "APA") to acquire the non-clinical assets of the Seller’s owned and operated fertility clinic in Indianapolis, Indiana (the "Clinic") for a combined purchase price of $750,000”
INVO Fertility, Inc. entered into Registration Rights Agreement with institutional investor (effective 2025-12-02).
“Further, in connection with the Private Placement, on December 2, 2025, the Company entered into that certain registration rights agreement (the “Registration Rights Agreement”), by and among the Company and the Purchaser, pursuant to which the Company agreed, among other things, to prepare and file with the Securities and Exchange Commission a Registration Statement”
INVO Fertility, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2025-12-02).
“Also in connection with the Private Placement, on December 2, 2025, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”), pursuant to which (i) the Placement Agent agreed to act as exclusive placement agent on a “reasonable best efforts” basis in connection with the Private Placement”
INVO Fertility, Inc. entered into Securities Purchase Agreement with institutional investor valued at approximately $4,000,000 (effective 2025-12-02).
“On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000”
INVO Fertility, Inc. issued warrants to purchase up to 118,343 shares of Common Stock of warrant to placement agent for acting as placement agent.
“the Company agreed to pay the Placement Agent an aggregate fee equal to 8.0% of the gross proceeds raised in the Private Placement and warrants to purchase up to 118,343 shares of Common Stock at an exercise price of $2.1125 per share (the "Placement Agent Warrants").”
INVO Fertility, Inc. issued prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock, and common stock purchase warrants to purchase 4,733,728 shares of Common of warrant to institutional investor for gross proceeds of approximately $4,000,000.
“On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with an institutional investor (the "Purchaser"), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000, comprised of 235,000 shares (the "Shares") of common stock par value $0.0001 per share (the "Common Stock"), prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock (the "Pre-Funded Warrants"), and common stock purchase warrants to purchase 4,733,728 shares of Common Stock (the "Common Warrants"), to the Purchaser in a private placement (the "Private Placement").”
INVO Fertility, Inc. issued 235,000 shares of common stock of common stock to institutional investor for gross proceeds of approximately $4,000,000.
“On December 2, 2025, INVO Fertility, Inc., a Nevada corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with an institutional investor (the "Purchaser"), pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4,000,000, comprised of 235,000 shares (the "Shares") of common stock par value $0.0001 per share (the "Common Stock"), prefunded common stock purchase warrants to purchase 2,131,864 shares of Common Stock (the "Pre-Funded Warrants"), and common stock purchase warrants to purchase 4,733,728 shares of Common Stock (the "Common Warrants"), to the Purchaser in a private placement (the "Private Placement").”
INVO Fertility, Inc.: 1-for-8 reverse stock split of common stock and reduction in authorized shares from 50,000,000 to 6,250,000, effected by filing a Certificate of Change with the Nevada Secretary of State (effective 2025-11-28).
“On November 26, 2025, the Company filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-8 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of Common Stock.”
INVO Fertility, Inc. issued 500 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $500,000 in cash.
“a party pursuant to a joinder agreement (the “ Joinder Agreement ”) on October 11, 2024), to acquire 500 shares of C-2 Preferred, with an aggregate stated value of $500,000, for $500,000 in cash. As a result of the exercise, the conversion price on the C-2 Preferred adjusted to $0.6285 per share. The C-2 Preferred issued pursuant to this exercise were”
INVO Fertility, Inc. issued 200 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $200,000 in cash.
“to acquire 200 shares of C-2 Preferred, with an aggregate stated value of $200,000, for $200,000 in cash.”
INVO Fertility, Inc. issued 400 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder for $400,000.
“became a party pursuant to a joinder agreement (the “ Joinder Agreement ”) on October 11, 2024), to acquire 400 shares of C-2 Preferred, with an aggregate stated value of $400,000, for $400,000 in cash. As a result of the exercise, the conversion price on the C-2 Preferred adjusted to $0.7141 per share. The C-2 Preferred issued pursuant to this exercise were”
INVO Fertility, Inc. issued 467 additional shares of Series C-2 Preferred Stock of preferred stock to Five Narrow Lane LP for aggregated stated value of 1,334,000.
“the Company and Five Narrow Lane LP, a Delaware limited partnership (“ FNL ”) entered into an agreement (the “ Exchange Agreement ”) pursuant to which FNL agreed to exchange a Second Amended and Restated Senior Secured Convertible Debenture Due February 11, 2026 (the “ Second Amended and Restated Debenture ”) held by FNL for receipt of shares of Series C-2 Convertible Preferred Stock (the “ Series C-2 Preferred Stock ”) with an aggregated stated value of 1,334,000. In consideration thereof, the Company agreed to issue 467 additional shares of Series C-2 Preferred Stock to FNL.”
INVO Fertility, Inc. issued 200 shares of C-2 Preferred of preferred stock to an institutional investor and existing holder (the “Holder”) for $200,000 in cash.
“to acquire 200 shares of C-2 Preferred, with an aggregate stated value of $200,000, for $200,000 in cash.”
INVO Fertility, Inc. engaged WithumSmith+Brown, PC as its auditor.
“On September 5, 2025, the Audit Committee approved the engagement of WithumSmith+Brown, PC (“Withum”) effective immediately as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2025.”
INVO Fertility, Inc. dismissed M&K CPAS, PLLC as its auditor.
“On September 3, 2025, INVO Fertility, Inc. (the “Company”) notified M&K CPAS, PLLC (“M&K”) of its dismissal, effective September 5, 2025, as the Company’s independent registered accounting firm.”
INVO Fertility, Inc.: 1-for-3 reverse stock split of common stock, with proportionate reduction in authorized shares and adjustments to options/warrants (effective 2025-07-21).
“On July 18, 2025, INVO Fertility, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-3 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split became effective at 12:01 a.m., Eastern Time, on Monday, July 21, 2025”
INVO Fertility, Inc.: Filed Certificate of Amendment to Certificate of Designation of Series C-2 Convertible Preferred Stock, amending rights, preferences, and privileges of the C-2 Preferred, authorizing 20,000 shares with a stated value of $1,000 per share, adjusting conversion price, and setting dividend and liquidati (effective 2025-06-27).
“On June 27, 2025, we filed with the Nevada Secretary of State a Certificate of Amendment to Certificate of Designation of the Series C-2 Non-Voting Convertible Preferred Stock of the Company (the “ Certificate of Amendment ”), which amends and restates the rights, preferences, and privileges of the C-2 Preferred.”
INVO Fertility, Inc. completed a disposition (closed 2025-06-02).
“Effective June 2, 2025, INVO Fertility, Inc., a Nevada corporation (the “ Company ”) consummated the divestiture of a majority of its holdings in NAYA Therapeutics Inc., a Delaware Corporation (“ NTI ”).”
Dr. Daniel Teper resigned as President at INVO Fertility, Inc..
“On May 28, 2025, Dr. Daniel Teper resigned as President of the Company.”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“April 16, 2025, INVO Fertility, Inc. (the “Company”), formerly known as NAYA Biosciences, Inc., received a letter (the “Letter”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company failed to file its Annual Report on Form 10-K for the year ended December 31, 2024 (the “Filing”), on a timely basis and, as such, no longer satisfies Nasdaq Listing Rule 5250(c)(1) (the “Rule”). The Letter has no immediate effect on the listing of the Company’s common stock and the Company’s common stock continues to trade on The Nasdaq Capital M”
INVO Fertility, Inc.: Company changed its corporate name to INVO Fertility, Inc. via an Amendment to Articles of Incorporation filed with Nevada Secretary of State on April 14, 2025 (effective 2025-04-14).
“On April 14, 2025, the Company changed its corporate name to INVO Fertility, Inc., pursuant to an Amendment to Articles of Incorporation filed with the Nevada Secretary of State on April 14, 2025 (the “Name Change”).”
INVO Fertility, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“March 31, 2025, the Company evidenced a closing bid price of at least $1.00 per share for 10 consecutive business days and, on March 31, 2025, the Staff determined that the Company has regained compliance with the Rule. Accordingly, the Company’s securities are no longer subject to delisting and the listing matter has been closed.”
INVO Fertility, Inc.: Amended certificate of incorporation to effect a 1-for-12 reverse stock split of common stock and adjust authorized shares from 50,000,000 to 4,166,667 (effective 2025-03-18).
“On March 18, 2025, NAYA Biosciences, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-12 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”).”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).
“January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 5801(s)(2)(G) that require companies listed on The Nasdaq Capital Market to hold an annual meeting of shareholders (an “ASM”) within twelve months of the fiscal year’s end (the “ASM Rule”). The Company did not hold an ASM in its fiscal year ended December 31, 2024. The Notice has no immediate effect on the listing of the Company’s common stock and the Company’s common stock conti”
INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).
“January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58”
INVO Fertility, Inc.: Company changed its corporate name to NAYA Biosciences, Inc. via an Amendment to Articles of Incorporation (effective 2024-10-15).
“On October 15, 2024, the Company changed its corporate name to NAYA Biosciences, Inc., pursuant to an Amendment to Articles of Incorporation filed with the Nevada Secretary of State on October 15, 2024 (the “ Name Change ”).”
INVO Fertility, Inc. completed an acquisition involving NAYA Biosciences, Inc. for 118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock (closed 2024-10-11).
“f NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”) pursuant to an Amended and Restated Agreement and Plan of Merger by and among the Company, NAYA, and INVO Merger”
INVO Fertility, Inc. underwent a change of control involving NAYA Biosciences, Inc. for 118,148 shares of the Company's common stock and 30,375 shares of the Company's newly-designated Series C-1 Convertible Preferred Stock (closed 2024-10-11).
“f NAYA Biosciences, Inc., a Delaware corporation (“ NAYA ”) pursuant to an Amended and Restated Agreement and Plan of Merger by and among the Company, NAYA, and INVO Merger”
Lyn Falconio was appointed as Director at INVO Fertility, Inc..
“the Company’s board of directors appointed Dr. Daniel Teper and Lyn Falconio as directors of the Company to fill two vacancies on the board.”
Daniel Teper was appointed as President at INVO Fertility, Inc..
“the board of directors appointed Dr. Teper as President of the Company.”
Daniel Teper was appointed as Director at INVO Fertility, Inc..
“the Company’s board of directors appointed Dr. Daniel Teper and Lyn Falconio as directors of the Company to fill two vacancies on the board.”
INVO Fertility, Inc. reported financial results for the first quarter of 2024.
“On May 15, 2024, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the period ended March 31, 2024.”
INVO Fertility, Inc. terminated a lease with Brown Fertility Associates PA (effective 2024-04-19).
“On April 19, 2024, INVO Centers LLC ("INVO Centers"), a wholly owned subsidiary of INVO Bioscience, Inc. (the "Company"), completed the assignment to Brown Fertility Associates PA ("Brown Fertility") of its lease with 4602 North Armenia Ave, LLC (the "Landlord"), for the property located at 4602 North Armenia Avenue, Suite 200, Tampa, LLC (the "Premises").”
INVO Fertility, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 17, 2024, the Company, having reported, on April 16, 2024, stockholders’ equity of $892,825 in the Form 10-K for the period ended December 31, 2023, received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) that requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Equity Rule”). In a decision dated November 22, 2023, a Nasdaq Hearings Panel (the “Panel”) previously had confirmed that the Company reg”
INVO Fertility, Inc. amended Amendment to the Warrant Agent Agreement with Transfer Online, Inc. (effective 2024-04-17).
“On April 17, 2024, the Company and the Warrant Agent entered into an Amendment to the Warrant Agent Agreement (the “Amendment”) to confirm that the Company may adjust the exercise price of the of the Warrants to provide an exercise price per share that is lower than the then-current exercise price of the Warrants.”
INVO Fertility, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $1,381,754, net income $(2.0) million.
“INVO Reports Fourth Quarter and Full Year 2023 Financial Results SARASOTA, Fla., April 16, 2024 -- INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture (“IVC”) procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a business update. Q4 2023 Financial Highlights (all metrics compared to Q4 2022 unless otherwise noted) ● Revenue was $1,381,754, an increase of 397% compared to $278,142. ● Clinic revenue increased 519% to $1,362,938, compared to $220,253. All reported clinic revenue is derived from the Company’s INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin which are consolidated in the Company’s financial statements. ● Revenue from all clinics, incl”
INVO Fertility, Inc. incurred convertible notes of $275,000.00 with FirstFire Global Opportunities Fund, LLC at twelve percent (12%) per annum maturing twelve (12) months from the issue date.
“On April 5, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with FirstFire Global Opportunities Fund, LLC (the “ Buyer ”), pursuant to which the Buyer agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $275,000.00, which is convertible into shares of the Company’s common stock”
INVO Fertility, Inc. entered into Purchase Agreement with FirstFire Global Opportunities Fund, LLC valued at $275,000 (effective 2024-04-05).
“On April 5, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with FirstFire Global Opportunities Fund, LLC (the “ Buyer ”), pursuant to which the Buyer agreed to purchase, and the Company agreed to issue and sell, (i) a promissory note with an aggregate principal amount of $275,000.00”
INVO Fertility, Inc. entered into Purchase Agreement with Triton Funds LP valued at up to $850,000 (effective 2024-03-27).
“On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Triton Funds LP (“ Triton ”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.